Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 1.00 |
| ▸ | HTR6 | P50406 | 9/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31109384 | 0.98 | HTR2C (1.00) | HTR2CHTR6HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL21855666 | 0.98 | HTR2C (1.00) | HTR2CHTR6HTR1ASLC6A2SLC6A4 | |
| SCHEMBL26530980 | 0.89 | HTR2C (0.80) | HTR2CHTR6 | |
| SCHEMBL16956125 | 0.86 | HTR2C (0.74) | HTR2CHTR6 | |
| SCHEMBL1513258 | 0.84 | HTR2C (1.00) | HTR2CHTR6HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL30011597 | 0.82 | HTR2C (1.00) | HTR2CHTR6HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL2803875 | 0.82 | HTR2C (1.00) | HTR2CHTR6HTR1ASLC6A2SLC6A4 | |
| SCHEMBL6386133 | 0.82 | HTR2C (0.69) | HTR2CHTR6HTR1A | |
| SCHEMBL24120164 | 0.81 | HTR2C (0.69) | HTR2CHTR6HTR1ASLC6A2SLC6A4 | |
| SCHEMBL6638482 | 0.81 | HTR2C (0.69) | HTR2CHTR6HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873464-B1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12091405-B2 | Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20210395240-A1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210395240-A1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210380572-A1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-09 | — | — | US | disclosed |
| EP-3873464-A1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-1930145-B | Cycloalkanopyridine derivative | MSD CO LTD | 2011-06-15 | — | — | CN | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| CN-1930145-A | Cycloalkanopyridine derivative | BANYU PHARMA CO LTD (JP) | 2007-03-14 | — | — | CN | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885HTR6 12/4885HTR1A 1/4885 |
| US-20210395240-A1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, TPH1 | HTR2C 273/4885HTR6 328/4885HTR1A 246/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885HTR6 12/4885HTR1A 1/4885 |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | HTR2C 340/4885HTR6 421/4885HTR1A 368/4885 |
| US-12091405-B2 | Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, KYNU | HTR2C 289/4885HTR6 341/4885HTR1A 283/4885 |
| US-20210380572-A1 | NOVEL ARYLALKYL PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, AADAC | HTR2C 215/4885HTR6 231/4885HTR1A 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.